

ANNUAL RATES Past Est'd '11-'13 10 Yrs. to '17-'19 of change (per sh) Sales 5 Yrs. 5.5% 6.0% 8.5% 9.5% 6.5% 9.0% 14.0% 16.5% 25.0% 11.5% 15.0% 45.0% 'Cash Flow' Earnings Dividends Book Value 13.5%

Cal- endar	QUARTERLY SALES (\$ mill.) E Mar.Per.Jun.Per.Sep.Per. Dec.Per.				Full Year
2011	642.3	674.9	701.0	731.1	2749.3
2012	690.6	696.4	725.2	809.7	2921.9
2013	779.3	787.6	804.8	822.6	3194.3
2014	782.0	808.3	830	864.7	3285
2015	815	840	870	895	3420
Cal-	EARNINGS PER SHARE A				Full
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2011	.58	.57	.54	.53	2.22
2012	.66	.56	.66	.57	2.45
2013	.76	.61	.76	.65	2.79
2014	.73	.65	.81	.81	3.00
2015	.85	.75	.90	.85	3.35
Cal-	QUARTERLY DIVIDENDS PAIDB				Full
endar	Mar.31	Jun.30	Sep.30	Dec.31	Year
2010	.07	.07	.085	.085	.31
2011	.17	.17	.17	.17	.68
2012	.24	.24	.24	.24	.96
2013	.28	.28	.28	.28	1.12
2014	.31	.31			

ance appears to be regaining earlier form. Following a tough start in 2014, the June quarter ended more favorably. Although sales growth remained modest, share earnings came in higher than we expected at \$0.65, three pennies ahead of our call and \$0.04 above a year ago. We believe the spending frenzy to promote new brands ought to continue to drive volumes, though it may be at the expense of temporarily delayed margin growth. Nonetheless, the company's net profits are poised to pick up steam in the second half of the year, with the bulk of the advance likely generated during the fourth quarter.

competition aside, should benefit from market share gains over the next several quarters. In spite of notable headwinds, including pricing pressure and challenging category growth, promotional efforts have paid off, as megabrands *OxiClean*, *Avid*, and Trojan have enjoyed better market penetration. The ability of these brands to pick up share in the personal care and household products categories indicates that once economic conditions gain steam, the company will probably reduce its slotting fee expense, as product launches will probably scale back a bit upon completion of its current round of rollouts. Moreover, a rebound in the vitamin category is expected, as the recent slowdown should be shortlived. These factors will likely help

support share-net growth into 2015.

The long-term strategy here ought to **bear fruit.** C&D has a three-year rolling plan to hoist earnings, which includes new products, gross-margin improvement projects, enhanced operational efficiency, improvement and share repurchases. We look for better showings from specialty products to provide some upside. Moreover, diversifying the product portfolio has historically proven successful in shoring up demand. In addition, further acquisitions will probably aid growth potential, as C&D's strategy has proven beneficial in the past.

the downside, the stock offers limited potential for capital gains out to 2017-2019. The P/E multiple remains above historical levels. Investors should hold off for a more suitable entry point. September 26, 2014 Simon R. Shoucair

(A) Diluted earnings. Excl. nonrecur. gns.: '98 8¢; '02, 5¢; '03, 6¢; losses: '98, 2¢; '00, 39¢; '01, 17¢; '02, 7¢; '08, 8¢; '09, 7¢; '10, (21¢); '11, (10¢). Egs. may not sum due to rounding.

Incl. acquisition related charges: '04, 30¢. Next egs. rpt. due early Nov. (B) Div'd. are hist. paid in Mar., June, Sep., and Dec. ■ Dividend reinvestment plan available. (C) Incl. intang. In '13:

| 17.46/sh. (D) In millions, adusted for stock splits, (E) Sales from 2002 onward reflect accounting policies EITF 00-14 and EITF 00-25. Excl. amort. after 2009.

Company's Financial Strength Stock's Price Stability Price Growth Persistence 80 Earnings Predictability